Abstract:
Antibacterial compounds of structure (I) are disclosed, including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q3, R11 and R12 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
Abstract:
An improved process for converting gentamicin B to isepamicin comprising forming 3,6'-di-N-formylgentamicin B, acylating the 1-amino group with an N-protected (S)-isoserine compound and removing all the blocking groups under conditions which result in high yields of isepamicin. A novel formylating agent, 2-formylmercaptobenzothiazole, and intermediate compounds are also disclosed.
Abstract:
Область применения: Изобретение относится к комбинаторной химии, фармации и косметологии, позволяет синтезировать новые комбинаторные библиотеки производных антибиотиков для применения в фармации, косметологии и фармации. Суть изобретения: новые комбинаторные производные антибиотиков на основе супрамолекулярных структур, отличающиеся тем, что супрамолекулярные структуры (В) получены путем комбинаторного синтеза из одной исходной молекулы полифункционального антибиотика (А1) с двумя и более доступными для ковалентной модификации группами в реакции, как минимум, с двумя разными модификаторами (М2 и М3) одновременно согласно схеме синтеза m А1+k М2 + k М3=m В, при этом образуется комбинаторная смесь модифицированных производных исходной молекулы, с максимальным разнообразием производных, а в качестве биологически активных веществ для создания фармацевтических композиций используют цельную комбинаторную смесь в виде супрамолекулярной структуры без разделения на индивидуальные компоненты, а в реакции образуется комбинаторная смесь В модифицированных производных исходной молекулы антибиотика (А1), количество комбинаций которых является максимальным (m). Технический результат: модифицированные комбинаторные производные антибиотиков с антимикробной и антигрибковой активностью в отношении мультирезистентных и полирезистентных штаммов микроорганизмов и грибов. Средства имеют широкий спектр действия, а супрамолекулярная и комбинаторная структура их десятков и сотен производных исключает привыкание микроорганизмов.
Abstract:
The present invention provides new aminoglycoside dosing regimens associated with enhanced microbicidal activity and reduced nephrotoxicity, as well as methods of using these dosing regimens to treat various bacterial infections.
Abstract:
A high yielding process for converting 3,2',6'-tri-N-acetyl sisomicin to netilmicin comprising the step of silylating the starting material at the 5,2'' positions, and optionally at the 4'' position, converting the 1-amino substituents to a 1-N-imino substituent, converting the imino to an ethylamino, deprotecting the compound and recovering netilmicin. Also disclosed are novel intermediate compounds.
Abstract:
Novel guanylated glycosides of deoxystreptamine possibly substituted by a second carbohydrate radical and/or by an amidino or an acyl radical on one of the amine groups, which are useful as anti-bacterially active antibiotics.
Abstract:
This disclosure relates generally to aminoglycoside derivatives of Formula (I) as described herein. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating bacterial infections by administering these compounds and pharmaceutical compositions to subjects in need thereof.
Abstract:
A preparation of antibiotic G418 with low cell toxicity and high purity, and methods of preparing such a preparation, are provided. More specifically, an isolated antibiotic G418 with a purity of greater than 95% and no individual group of gentamicin impurities exceeding 3%, as measured by HPLC, is described. Uses of this high purity antibiotic G418 include, for example, for in vitro cell selection.
Abstract:
Antibacterial compounds of structures (I) and (II) are disclosed, including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q3, R1, R2, R3, R11 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
Abstract:
Antibacterial compounds of structures (I) and (II) are disclosed, including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q3, R1, R2, R3, R11 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.